Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer (Q37230157)

19 August 2017

Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer (English)

1 reference

19 August 2017

1 reference

12

Yung-Jue Bang

1 reference

19 August 2017

9

Seock-Ah Im

1 reference

19 August 2017

5

Do-Youn Oh

1 reference

19 August 2017

10

Tae-You Kim

1 reference

19 August 2017

11

Dae Seog Heo

1 reference

19 August 2017

Hye Jin Kim

1

1 reference

19 August 2017

Jin-Soo Kim

2

1 reference

19 August 2017

Myung-Deok Seo

3

1 reference

19 August 2017

So-Yeon Oh

4

1 reference

19 August 2017

Jee Hyun Kim

6

1 reference

19 August 2017

Se-Hoon Lee

7

1 reference

19 August 2017

Dong-Wan Kim

8

1 reference

19 August 2017

language of work or name

1 reference

30 June 2008

1 reference

Cancer Research and Treatment

19 August 2017

1 reference

19 August 2017

40

1 reference

19 August 2017

2

1 reference

19 August 2017

81-86

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

19 August 2017

start time

30 June 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Advanced breast cancer: a phase II trial with gemcitabine

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Gemcitabine: preclinical pharmacology and mechanisms of action.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Clinical characteristics of breast cancer patients in Korea in 2000.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

A unified definition of clinical anthracycline resistance breast cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2697482

The synthesis of Navelbine prototype of a new series of vinblastine derivatives

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19688053

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19688053

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19688053

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4143/CRT.2008.40.2.81

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19688053

1 reference